Drug Trial Radar · NCT06166836
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Oct 12, 2022
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- InxMed (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- InventisBio Co., Ltd
- First posted
- Dec 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.
Conditions
- Solid Tumor
Interventions
D1553Drug
D1553 orally taken,600mg twice a day
IN10018(Ifebemtinib)Drug
IN10018 orally taken once daily at approximately the same time each day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase II dose (RP2D) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutationTime frame: Through study completion, approximately 3 years
- Objective Response Rate (ORR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutationTime frame: Through study completion, approximately 3 years
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Hunan Cancer Hospital
Changsha, China
Fujian Cancer Hospital
Fuzhou, China
First Affiliated Hospital of Gannan Medical University
Ganzhou, China
General Hospital Of Eastern Theater Command
Nanjing, China
Renmin Hospital of Wuhan University
Wuhan, China
Xuzhou Central Hospital
Xuzhou, China
Henan Cancer Hospital
Zhengzhou, China
The first Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.